PROK

ProKidney Corp.'s stock has been impacted by several events in the past six months. The stock saw a decrease following the appointment of Greg Madison as Chief Commercial Officer and after reporting its full-year 2025 financial results. The stock increased after announcing its presentation at the 44th Annual J.P. Morgan Healthcare Conference and after reporting its third-quarter 2025 financial results. The stock rose after presenting full results from the Phase 2 REGEN-007 trial of Rilparencel at the American Society of Nephrology Kidney Week 2025. The stock experienced a surge following encouraging Phase 2 clinical trial outcomes for its REGEN-007 study. Overall, the stock has gained 154.9% over the past 12 months.